Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Iovance Biotherapeutics (IOVA) Misses Q3 EPS by 1c
November 4, 2019 4:02 PM ESTIovance Biotherapeutics (NASDAQ: IOVA) reported Q3 EPS of ($0.40), $0.01 worse than the analyst estimate of ($0.39).
We continue making great progress in developing tumor infiltrating lymphocyte (TIL) therapy, which could become the first approved cell therapy product for solid tumor indications, commented Maria Fardis, Ph.D.,... More
